United States: Congress Passes "SUPPORT For Patients And Communities Act" — A Rare Example Of Bi-Partisanship

Last Updated: October 16 2018
Article by Ken Yood and Theresa E. Thompson

In a September 14, 2018 Proclamation, President Donald Trump announced that the week of September 16 through September 22, 2018 would be Prescription Opioid and Heroin Epidemic Awareness Week ("Awareness Week"). As described in the Proclamation, the goal of Awareness Week is to "raise awareness about the prescription opioid and heroin epidemic and to consider concrete follow up activities."

The SUPPORT Act: A Timeline

In the spirit of Awareness Week, Congress took uncharacteristically swift action to complete the legislative process needed to send the "Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act" or the "SUPPORT for Patients and Communities Act" (the "SUPPORT Act") to President Trump's desk for signature.

On June 22, 2018, the House of Representatives passed, with rare bipartisan support, its version of the SUPPORT Act. Immediately thereafter, the House version of the SUPPORT Act was sent to the Senate for the Senate's consideration and approval.

On September 17, 2018, the Senate passed its version of the SUPPORT Act. The Senate version of the SUPPORT Act went back to the House for consideration.

On September 25, 2018, House and Senate negotiators agreed on a final legislative package to address the opioid crisis.

On September 28, 2018, the House voted 393-8 to pass the negotiated SUPPORT Act.

On October 3, 2018, the Senate voted 98-1 to pass the negotiated SUPPORT Act as passed by the House on September 28, 2018.

Now passed by both the House and the Senate, the SUPPORT Act is currently headed for signature by President Trump. The President has announced his intention to sign the SUPPORT Act quickly.

The SUPPORT Act: Sum and Substance

According to a September 7, 2018 Press Release from the U.S. Senate Committee on Health, Education, Labor & Pensions, the opioid legislation is intended to: (1) reduce use and supply; (2) encourage recovery; (3) support caregivers and families; and (4) drive innovation and long-term solutions. Although there are some concerns about urgency and funding, the version of the SUPPORT Act headed to the President's desk includes provisions that aim to stop the entry of illegal drugs, provide for better drug monitoring communication between states, establish comprehensive opioid recovery centers, expand access to substance use disorder health professionals and medication-assisted treatment ("MAT"), improve plans of care and support for families and in schools and educational programs, progress research and development of strategies and technologies, and more. The SUPPORT Act will mean substantive changes to the Medicare and Medicaid programs, expanding services and aid for their vulnerable patient populations.

SUPPORT for Telemedicine

Also included in the SUPPORT Act are several provisions to support and expand telemedicine programs aimed at combatting opioid and heroin addiction. For example, states will receive guidance on options for providing telehealth services to address substance use disorders under Medicaid. Medicare coverage will be expanded for telehealth services furnished for treatment of substance use disorders and co-occurring mental health disorders, eliminating geographic restrictions on patient locations. Further, the Attorney General and the Secretary of the Department of Health and Human Services ("HHS") will be required by the SUPPORT Act to issue final regulations for special registration for health care providers to prescribe controlled substances via telemedicine in legitimate emergency situations, such as lack of access to an in-person specialist. The SUPPORT Act will also permit utilization of the Project Extension for Community Health Outcomes ("ECHO") model in comprehensive opioid recovery centers, enabling care coordination and services delivery through technology. A number of reports, evaluations, and assessments on the effectiveness of telemedicine services and technologies in substance use disorder treatment are also required.

In addition to the changes forthcoming under the SUPPORT Act, HHS and the Drug Enforcement Agency ("DEA") also want health care providers to know that telemedicine is not only an acceptable, but an encouraged, means of treating opioid use disorder ("OUD") under existing regulations and guidance.

In an HHS blog post entitled, "Secretary Price Announces HHS Strategy for Fighting Opioid Crisis" dated September 18, 2018, HHS emphasized that it, with the DEA, has developed materials "to help clarify how clinicians can use telemedicine as a tool to expand buprenorphine-based MAT for opioid use disorder treatment under current DEA regulations." Such materials, like a September 2018 statement issued by HHS entitled, "Telemedicine and Prescribing Buprenorphine for the Treatment of Opioid Use Disorder," make clear that the DEA and HHS have eased their restrictions to enable the use of telemedicine to curb the opioid crisis. Buprenorphine is a common medication used in MAT, described by the Substance Abuse and Mental Health Services Administration ("SAMHSA") as helping lower the potential for misuse, diminish the effects of physical dependency to opioids, and increase safety in cases of overdose.

Generally, buprenorphine may only be prescribed for the treatment of OUD in federally regulated opioid treatment programs. To prescribe buprenorphine for this purpose outside of such a setting, practitioners must have a waiver under the Drug Addiction Treatment Act of 2000 ("DATA 2000"). Now, in accordance with a statement released by the DEA on May 15, 2018, titled "Use of Telemedicine While Providing Medication Assisted Treatment (MAT)," HHS and the DEA have made it clear that providers with DATA 2000 waivers may prescribe buprenorphine for the treatment of OUD via "an appropriately safeguarded interactive telecommunications system," as long as a DEA-registered practitioner is present (whether in-person or via electronic communication) at the consultation (the "Telemedicine OUD Treatment Policy"). This exemption from the in-person medical evaluation requirement is particularly relevant for rural areas, which have been especially impacted by the opioid crisis and which frequently endure health care provider shortages.

The Telemedicine OUD Treatment Policy is in keeping with HHS's "5-Point Strategy to Combat the Opioid Crisis," launched in 2017. According to the "comprehensive strategy," HHS has identified five specific tactics for the fight against OUD:

  • Improving access to treatment and recovery services;
  • Promoting use of overdose-reversing drugs;
  • Strengthening our understanding of the epidemic through better public health surveillance;
  • Providing support for cutting edge research on pain and addiction; and
  • Advancing better practices for pain management.

Certainly, the Telemedicine OUD Treatment Policy speaks directly to HHS's first strategic imperative – to increase access to treatment and recovery services – by expanding the availability and utility of telemedicine services.

The Sheppard Mullin Healthcare Law Blog has covered similar recent developments in telemedicine and telehealth, such as changes to the Texas Medical Board telemedicine regulations, exceptions to the Haight Act, and pending actions in the realm of online prescribing.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
22 Oct 2019, Roundtable, Los Angeles, United States

Please join us for Sheppard Mullin's Ethics and Eggs: A Breakfast Roundtable to Discuss Ethics Issues in IP Matters.

23 Oct 2019, Other, Dallas, United States

Marketing Wants To Do What? Sweepstakes, Influencers, Loyalty, and Other Advertising and Promotional Fun

25 Oct 2019, Webinar, Los Angeles, United States

Matthew Bonovich will be a speaker at this webinar.

State and local governments continue to incentivize renewable energy and battery storage, causing an increase in mergers and acquisitions among producers and specialized renewables.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions